IL147541A0 - Oligonucleotides for inhibiting the expression of human eg5 - Google Patents

Oligonucleotides for inhibiting the expression of human eg5

Info

Publication number
IL147541A0
IL147541A0 IL14754100A IL14754100A IL147541A0 IL 147541 A0 IL147541 A0 IL 147541A0 IL 14754100 A IL14754100 A IL 14754100A IL 14754100 A IL14754100 A IL 14754100A IL 147541 A0 IL147541 A0 IL 147541A0
Authority
IL
Israel
Prior art keywords
oligonucleotides
inhibiting
expression
human
Prior art date
Application number
IL14754100A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL147541A0 publication Critical patent/IL147541A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL14754100A 1999-07-28 2000-07-21 Oligonucleotides for inhibiting the expression of human eg5 IL147541A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19935303A DE19935303A1 (de) 1999-07-28 1999-07-28 Oligonukleotide zur Inhibierung der Expression von humanem eg5
PCT/EP2000/007345 WO2001007602A2 (de) 1999-07-28 2000-07-21 Oligonukleotide zur inhibierung der expression von humanem eg5

Publications (1)

Publication Number Publication Date
IL147541A0 true IL147541A0 (en) 2002-08-14

Family

ID=7916259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14754100A IL147541A0 (en) 1999-07-28 2000-07-21 Oligonucleotides for inhibiting the expression of human eg5

Country Status (26)

Country Link
US (1) US6472521B1 (de)
EP (1) EP1204742A2 (de)
JP (1) JP2003505080A (de)
KR (1) KR20020033744A (de)
CN (1) CN1165617C (de)
AR (1) AR024953A1 (de)
AU (1) AU6568200A (de)
BR (1) BR0013180A (de)
CA (1) CA2380192A1 (de)
CZ (1) CZ2002324A3 (de)
DE (1) DE19935303A1 (de)
EE (1) EE200200044A (de)
HK (1) HK1048337B (de)
HR (1) HRP20020075A2 (de)
HU (1) HUP0202794A3 (de)
IL (1) IL147541A0 (de)
MX (1) MXPA02000817A (de)
NO (1) NO20020365L (de)
NZ (1) NZ516839A (de)
PL (1) PL353733A1 (de)
RU (1) RU2249458C2 (de)
SK (1) SK1162002A3 (de)
TR (1) TR200200201T2 (de)
WO (1) WO2001007602A2 (de)
YU (1) YU91901A (de)
ZA (1) ZA200200655B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6440686B1 (en) 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
WO2004074301A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Differentially expressed nucleic acids that correlate with ksp expression
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
EP1737979B9 (de) * 2004-03-23 2011-09-21 Oncotherapy Science, Inc. Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
ES2544861T3 (es) * 2006-03-31 2015-09-04 Alnylam Pharmaceuticals Inc. Composiciones y métodos para inhibir la expresión del gen Eg5
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
CN101453891B (zh) * 2006-05-26 2013-12-11 雷加多生物科学公司 Reg1抗凝系统的给药
PT2207787E (pt) * 2007-11-06 2015-02-17 Adiutide Pharmaceuticals Gmbh Análogos de oligorribonucleótidos imunoestimulantes contendo frações de oligofosfato modificadas
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
DK2750768T3 (en) 2011-08-30 2019-01-21 Astex Pharmaceuticals Inc DECITABINE INDIVIDUAL FORMULATIONS
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
CA2921839A1 (en) * 2013-08-28 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
WO2015054676A2 (en) * 2013-10-11 2015-04-16 Isis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
KR102369736B1 (ko) * 2014-05-01 2022-03-02 아이오니스 파마수티컬즈, 인코포레이티드 보체 인자 b 발현을 조절하기 위한 조성물 및 방법
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171066A3 (de) 1984-08-09 1989-02-01 Siemens Aktiengesellschaft Verfahren und Schaltungsanordnung zum Adressieren von Signalabgabe-/Signalaufnahmeeinrichtungen von einer zentralen Verarbeitungseinrichtung her
DE59108644D1 (de) 1990-07-02 1997-05-07 Hoechst Ag Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
NZ245720A (en) 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
DE59306170D1 (de) 1992-09-24 1997-05-22 Hoechst Ag Oligoribonucleotid- und Ribozym-Analoga mit terminalen 3'-3'-bzw.5'-5'-Verknüpfungen
GB9311113D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Probes
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
PT739898E (pt) 1995-03-13 2002-03-28 Aventis Pharma Gmbh Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao
US6309821B1 (en) * 1996-05-16 2001-10-30 Incyte Genomics, Inc. DNA encoding a PAC10 human homolog
AU8656098A (en) * 1997-07-23 1999-02-16 Brigham And Women's Hospital Lens epithelial cell derived growth factor
EP1053319A2 (de) * 1998-01-28 2000-11-22 Chiron Corporation Menschliche gene und expressionsprodukte ii

Also Published As

Publication number Publication date
DE19935303A1 (de) 2001-02-08
US6472521B1 (en) 2002-10-29
MXPA02000817A (es) 2002-07-30
SK1162002A3 (en) 2002-06-04
HK1048337B (zh) 2005-02-25
ZA200200655B (en) 2003-09-23
CN1367828A (zh) 2002-09-04
RU2249458C2 (ru) 2005-04-10
HUP0202794A3 (en) 2006-03-28
KR20020033744A (ko) 2002-05-07
BR0013180A (pt) 2002-04-09
EP1204742A2 (de) 2002-05-15
CA2380192A1 (en) 2001-02-01
NO20020365D0 (no) 2002-01-23
NZ516839A (en) 2004-04-30
PL353733A1 (en) 2003-12-01
HUP0202794A2 (en) 2003-03-28
JP2003505080A (ja) 2003-02-12
WO2001007602A3 (de) 2001-05-17
NO20020365L (no) 2002-03-25
TR200200201T2 (tr) 2002-05-21
YU91901A (sh) 2003-02-28
HK1048337A1 (en) 2003-03-28
AR024953A1 (es) 2002-10-30
WO2001007602A2 (de) 2001-02-01
HRP20020075A2 (en) 2005-10-31
CZ2002324A3 (cs) 2002-05-15
EE200200044A (et) 2003-06-16
CN1165617C (zh) 2004-09-08
AU6568200A (en) 2001-02-13

Similar Documents

Publication Publication Date Title
IL147541A0 (en) Oligonucleotides for inhibiting the expression of human eg5
IL149694A0 (en) Therapeutic uses of lna-modified oligonucleotides
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
IL148719A0 (en) Kinase inhibitors as therapeutic agents
AU142262S (en) Towel
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
PL355101A1 (en) Use of h1
PL346170A1 (en) Short oligonucleotides for the inhibition of vegf expression
GB9925900D0 (en) Patient thermometer
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL148166A0 (en) Drug for treating fractures
CA90059S (en) Towel
EP1218407A4 (de) Verwendungen von kappa-conotoxin pviia
EP1221963A4 (de) Methoden zur hemmung der osteoclastogenese
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
PL350963A1 (en) Use of arylalkanoylpyridazines
EP1194439A4 (de) Menschliches eag2
EP1240156A4 (de) 3-methylchroman- oder thiochromanderivate
CA86215S (en) Towel
CA86217S (en) Towel
IL132329A0 (en) Inhibition of dyslexia
GB9904070D0 (en) Inhibition of scale
CA86216S (en) Towel
CA86214S (en) Towel